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OBJECTIVES: We evaluated the validity and reliability of ultrasonography measurement of rectus femoris cross-
sectional area compared to computed tomography in patients in pre-dialysis chronic kidney disease and
analyzed the association between these measurements and the diagnosis of sarcopenia.
METHODS: One hundred patients with nondialysis chronic kidney disease were evaluated. Sarcopenia was
defined using the criteria of the Foundation for the National Institutes of Health Sarcopenia Project (FNIH). The
rectus femoris cross-sectional area was evaluated using ultrasonography and computed tomography.
RESULTS: The prevalence of sarcopenia was 29% according to the FNIH criteria. The difference in mean rectus
femoris cross-sectional area by ultrasonography and computed tomography was 3.97 mm, with a strong
correlation between the two methods (po0.001). Bland-Altman plot analysis showed good agreement between
computed tomography and ultrasonography. Rectus femoris cross-sectional area was significantly correlated
with muscle strength (r=0.300, p=0.002), lean body mass in the upper limbs (r=0.286, p=0.004), and lean body
mass in the lower limbs (r=0.271, p=0.006). The prevalence of sarcopenia was 12% (n=12) based on the
definition of low muscle mass according to ultrasonography of the rectus femoris cross-sectional area.
CONCLUSION: Ultrasonography was demonstrated to be a valid and reliable method for evaluating the rectus
femoris cross-sectional area in patients in pre-dialysis chronic kidney disease.
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’ INTRODUCTION
Sarcopenia is defined as an age-related progressive loss
of muscle mass, coupled with a decline in muscle strength
and physical performance (1,2). It is associated with impai-
red health status, mobility disorders, increased risk of falls
and fractures, difficulty in performing activities of daily
living, disability, loss of independence, and increased risk of
death (1-3).
Among individuals with chronic kidney disease (CKD),
sarcopenia may affect approximately 37% of dialysis patients
(1,2,4). The prevalence in patients in pre-dialysis CKD stages
ranges from 5 to 9% (5). Muscle mass loss in this population
is associated with greater morbidity and mortality as well
as an increase in cardiovascular complications and protein-
energy wasting (PEW) syndrome (1,2,6,7). One potential
important cause of sarcopenia in this population is a low-
protein diet for the conservative management of CKD in pre-
dialysis stages (8). Thus, early identification of sarcopenia
and evaluation of possibly modifiable risk factors are of
paramount importance in this patient population (1).
In recent years, varying definitions of sarcopenia have
been proposed, but no consensus exists regarding its char-
acterization (1,2). The European Working Group on Sarco-
penia in Older People (EWGSOP) proposed a set of criteria
in 2010 that is widely used in clinical practice and research
(1-3). Recently, new definitions have been proposed by the
Foundation for the National Institutes of Health Sarcopenia
Project (FNIH) (9). The criterion proposed by the FNIH
adjusts the appendicular lean mass evaluated by dual-energy
X-ray absorptiometry (DXA) according to the patient’s body
mass index (BMI). This method is based on the largest
epidemiological study with cross-validation analysis per-
formed to date for the classification of sarcopenia (9).
Several techniques can be used for muscle mass evalua-
tion, such as DXA, bioimpedance analysis (BIA), magneticDOI: 10.6061/clinics/2018/e392
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resonance imaging (MRI) and computed tomography (CT)
(3). Computed tomography (CT) is considered one of the
gold standards, but it exposes the patient to ionizing radia-
tion and is expensive and of limited availability (10). An
alternative could be the ultrasonography (US), an imaging
method that has experienced extraordinary technological
advances in recent years and has the advantages of low cost,
high portability and bedside use. It allows evaluation of
specific muscles and has proven to be valid and reliable
when evaluating muscle mass, yielding results comparable
to CT (11,12).
Due to the aging population and consequent increase in
the prevalence of sarcopenia, it is essential to assess new
methods to evaluate muscle mass, ideally methods that
have a lower cost and that can be performed at the bed-
side. Therefore, the purpose of this study was to evaluate
the validity and reliability of measurement of rectus femoris
cross-sectional area (RFCSA) by US compared to CT for the
diagnosis of sarcopenia in pre-dialysis CKD.
’ MATERIALS AND METHODS
This was a cross-sectional, convenience sample-based
study that evaluated 100 pre-dialysis CKD patients aged 65
years or older, of both genders, from the CKD outpatient
clinic of the Hiperdia Minas Center in Juiz de Fora, Brazil.
This was an additional analysis of the same population
previously described in another study by our group (2). Data
were collected between September 2014 and March 2016. The
study was approved by the local ethics committee, and each
patient signed an informed consent form. Patients who had
difficulty in performing the necessary muscle strength and
functional tests were excluded, along with those with severe
neuropathy, liver disease, stroke sequelae, arthritis, arthrosis,
amputations, severe chronic obstructive pulmonary disease
(COPD), Parkinson’s disease, cancer, or acquired immune
deficiency syndrome (AIDS) (2).
Diagnosis and classification of CKD were based on the
Kidney Disease Improving Global Outcomes (KDIGO) cri-
teria (13) and the glomerular filtration rate was estimated
from the serum creatinine levels using the CKD Epidemiol-
ogy Collaboration (CKD-EPI) equation (14). As described
previously, systemic hypertension was defined as a systolic
blood pressure (BP) equal to or greater than 140 mmHg and
a diastolic BP equal to or greater than 90 mmHg or the use
of antihypertensive medications (2,15). Diabetes mellitus
was defined as fasting blood glucose greater than or equal to
126 mg/dL or the use of antiglycemic drugs (2,15).
Blood samples were collected after 12 hours of fasting for
evaluation of blood count and creatinine (2).
Sarcopenia was defined according to the FNIH Sarcopenia
Project criteria (9). After 12 hours of fasting, patients under-
went DXA using GE Lunar Prodigy Primo equipment to
evaluate muscle mass and establish the prevalence of sarco-
penia according to the FNIH definition (2,9). Low muscle
mass was defined based on the Appendicular Lean Mass
Index (ALMI), with the following formula: appendicular lean
mass divided by BMI. Muscle mass was considered low
when the ALMI was below 0.789 for males and 0.512 for
females (2,9).
Handgrip strength was used to evaluate muscle strength,
with a cutoff point under 26 kg for males and under 16 kg for
females. Muscle performance was evaluated by calculating
the usual walking speed over a distance of 3 meters, and a
speed lower than 0.8 m/s indicated low performance (9).
Sarcopenia was defined as the presence of low muscle
mass with reduced muscle strength or performance.
Evaluation of RFCSA using US and CTwas performed by a
single experienced examiner. RFCSA was measured by B-
mode ultrasound on a Siemens Sonoline G40 (Korea, 2007)
device using a 6-12 MHz linear transducer. The transducer
was placed perpendicularly and transversely to the long axis
of the thigh with excessive use of contact gel and minimum
pressure to avoid muscle compression. RFCSA was measured
at the midpoint between the anterior iliac spine and the
upper lateral epicondyle of the femur. The measurements
were performed on the dominant leg, with the patient in
supine position, with legs extended and relaxed and toes
pointing to the ceiling. The dominant leg was determined
to be the leg used to climb the first rung of a ladder. A set
of three measurements was taken, including one at the
midpoint and the others 1 cm above and below this point.
RFCSA was measured by placing the cursor on its inner edge,
immediately below the external and internal muscle fascia in
all patients (Figure 1).
Tomographic images were obtained using a Siemens
Emotion device (Germany, 2007). RFCSA measurements were
performed on the same leg and at the same point marked
during the US evaluation, with the patient lying supine. The
slices were 0.63 cm thick and were acquired 1 cm above and
1 cm below the predetermined midpoint with a low-
radiation protocol (Figure 1). The CT measurement data sets
were analyzed in a blinded and randomized manner.
Statistical analysis
All statistical analyses were performed using SPSS soft-
ware version 21.0, with a statistical significance threshold of
po0.05.
In accordance with well-established methods, the results
were expressed as the mean and standard deviation for
continuous variables unless otherwise specified. Categorical
variables were expressed as percentages.
A paired t-test was used to evaluate the difference between
the RFCSA means as evaluated by US and CT, and the
correlations between the two methods and clinical variables
were evaluated using Pearson’s correlation coefficient.
Bland-Altman plot analysis (16) was used to evaluate
agreement between RF measurements performed by US
and CT. The Y-axis shows the difference between RFCSA
measurements by US and CT, and the X-axis shows the
mean CT and US observations. The mean of the differences
as well as the 95% confidence interval for differences are
also presented.
Receiver operating characteristic (ROC) curve analysis was
used to establish a cutoff point for reduced muscle mass
based on the RFCSA as evaluated by US. The area under the
curve (AUC) was used to calculate the sensitivity, specificity
and negative predictive value (NPV) of the selected cutoff
points according to gender.
’ RESULTS
The mean age of the studied population was 73.5±9.22
years, and 59 patients were female. Most patients were in
CKD stages 3B (n=37) and 4 (n=29). All patients had
hypertension and 54 had diabetes.
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The clinical and laboratory characteristics of the study
population are shown in Table 1.
The difference in the mean RFCSA as evaluated by CT
and US was 3.92 mm (po0.001). The Pearson correlation
coefficient of US compared to CT measurements was 0.826
(po0.001) (Figure 2). The Bland-Altman plot analysis showed
good agreement between the CT and US measurements
(Figure 3).
Our results show correlations of RFCSA as evaluated by US
with muscle strength (r=0.300; p=0.002), lean body mass in
the upper limbs (LBMUL) (r=0.286; p=0.004), and lean body
mass in the lower limbs (LBMLL) (r=0.271; p=0.006).
The cutoff for reduced muscle mass, based on US-mea-
sured RFCSA as defined by the ROC curve was 13.2 mm, with
an AUC of 0.595 for males. The cutoff for females was
10.9 mm with an AUC of 0.619. The sensitivity, specificity,
and NPV of the measurements are shown in Table 2.
The prevalence of sarcopenia was 29% according to the
FNIH definition, using DXA to evaluate muscle mass. Our
study population had a 12% prevalence of sarcopenia based
on the criterion for low RF muscle mass as assessed by US.
The prevalence was 8.3% (n=1) in stages 2 and 3A of CKD
and 91.6% (n=11) in stages 3B, 4 or 5 (po0.001).
’ DISCUSSION
Our study demonstrated that US can be used as a reliable
and valid method for the evaluation of muscle mass by mea-
suring the RFCSA in pre-dialysis CKD. Our results demon-
strate that sarcopenia can be diagnosed with a rapid imaging












Systolic blood pressure (mmHg) 152.0±25.74
Diastolic blood pressure (mmHg) 87.0±13.49
Total lean mass (kg) 41.8±8.67
ALM (kg) 17.8±3.89
ALMI (kg/BMI) 0.6±0.16
ALM in the upper limbs (kg) 4.6±1.23
ALM in the lower limbs (kg) 13.2±2.75
Handgrip (kg) 27.0±9.42
Walking speed (m/s) 0.8±0.48
Hemoglobin (g%) 12.4±1.75
Creatinine (mg/dL) 5.2 (1.00-6.24)
eGFR (ml/min/1.73 m2) 35.9±16.01
CDK: chronic kidney disease; ALM: appendicular lean mass; ALMI:
appendicular lean mass index; eGFR: estimated glomerular filtration rate.
Data are expressed as the mean±standard deviation, median (minimum-
maximum), or n.
Figure 1 - RFCSA evaluation by CT (A) and US (B). RFCSA: Cross-sectional area of the rectus femoris; CT: Computed tomography;
US: Ultrasound. Continuous green line: Rectus Femoris diameter as measured by CT; dotted yellow line: RFCSA as evaluated by US
Figure 2 - Pearson correlation coefficient of US compared to CT.
RFCSA: Rectus femoris cross-sectional area; CT: Computed tomo-
graphy; US: Ultrasound. The upper and lower lines represent the
95% confidence intervals.
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test that is simple to perform, easily interpreted and available
at the bedside.
Sarcopenia is associated with high morbidity and mortal-
ity in healthy older adults and patients with chronic diseases
(17) and is one of the main risk factors for the development
of frailty, falls, and fractures (18). The tests considered gold
standards for muscle mass evaluation and the diagnosis of
sarcopenia, such as CT and DXA, are costly, of limited avai-
lability, require trained personnel, and expose the patient to
radiation. Therefore, new methods need to be developed to
facilitate the diagnosis of sarcopenia.
Published data show that US can be used to assess muscle
mass in various situations. In 1994, Abe and colleagues sug-
gested that US could be used for the clinical evaluation of
muscle mass (19), and a few years later they published
predictive equations based on US for total and regional
skeletal muscle mass evaluation in healthy Japanese sub-
jects (20). In a recent publication, Scott and colleagues
found that US was a valid method for monitoring atrophy
and hypertrophy of the quadriceps and atrophy of the
gastrocnemius (21).
This association is also described in patients with chronic
diseases. Two studies have shown that US is a valid and
reliable method for evaluating muscle mass in patients with
COPD (22) and coronary artery disease (23).
Regarding CKD, two studies have used CT for quantifica-
tion of muscle mass and function in patients with end-stage
renal disease (ESRD) and on hemodialysis (24,25). Another
study also evaluated muscle mass by CT and assessed its
association with inflammatory markers in patients with
ESRD (26). However, to date, there is no published data on
the use of US to evaluate muscle mass in pre-dialysis CKD
stages, which makes our study the first to show that this
method is valid and reliable for the evaluation of muscle
mass in this population of patients.
In the general population, loss of both muscle mass and
muscle strength are related to unfavorable outcomes (27).
In CKD patients, Chang and colleagues showed that muscle
strength was an independent predictor of outcomes. Patients
with better handgrip strength showed better kidney survival,
and interventions aimed at affecting loss of muscle strength
could contribute to improvements in PEW, which is asso-
ciated with worse outcomes in this population (28). Our
study demonstrated an association between RFCSA as eval-
uated by US and muscle strength, as well as LBMUL and
LBMLL, suggesting that US would also be a useful method
for the evaluation of PEW in patients with CKD on conser-
vative treatment.
Once it has been shown that muscle mass can reliably
be determined by US, it is important to establish cutoff
points to be used in the diagnosis of sarcopenia. An Italian
study established cutoff points of 20 mm for males and 16 mm
for females for low muscle mass at specific muscle sites in
healthy elderly individuals using US (29). In the present
study, which evaluated elderly patients in pre-dialysis CKD
stages, the cutoff values of RFCSA were 13.25 mm for males
and 10.95 mm for females. These values, along with the
cutoff points recommended by the FNIH for muscle strength
and performance, allowed us to establish a prevalence of
sarcopenia of 12% in the studied population.
There is a well-established relationship between the preva-
lence of sarcopenia (as measured with traditional methods)
and worsening of kidney function, and we have demon-
strated this in a previous study in which we used the FNIH
sarcopenia criteria and DXA to evaluate muscle mass in
pre-dialysis CKD (2). In the present study, we also observed
a higher prevalence of sarcopenia among individuals with
more advanced CKD stages, using US to evaluate muscle mass.
Our study has limitations. The number of patients
included and the fact that the study was cross-sectional in
nature limited data analysis. Another important limitation
was the elderly population included, which may have
influenced the prevalence of sarcopenia, since there is an
age-related progressive loss of muscle mass. However, from
our point of view, the main limitation was the non-inclusion
of a population of young healthy subjects to establish cutoffs
that could be used to define low muscle mass based on US
measurement in the elderly population that was evaluated.
In conclusion, our results suggest that US-based estimation
of the RFCSA can be used by health professionals as a valid
and reliable method to evaluate muscle mass in patients with
CKD on conservative treatment, as it is associated with
muscle strength and mass. This finding overcomes a major
problem in the diagnosis of sarcopenia, which is the defini-
tion of muscle mass; until recently assessment of muscle
mass required costly methods to which most patients have
limited access. However, further studies involving a larger
number of participants and a control group of healthy young
Table 2 - Cutoff of the US-measured RFCSA, sensitivity, specificity, and NPV by gender.
RFCSA Sensitivity Specificity NPV
Males 13.2 mm 90% 70% 67.74% (95% CI 48.63 to 83.32)
Females 10.9 mm 94% 85% 67.31% (95% CI 52.89 to 79.67)
RFCSA: Rectus femoris cross-sectional area; NPV: Negative predictive value; US: Ultrasound; CI: Confidence interval.
Figure 3 - Bland-Altman plot of the differences between RFCSA
measurements by CT and US. RFCSA: Cross-sectional area of the
rectus femoris; CT: Computed tomography; US: Ultrasound; SD:
standard deviation. The bars represent the confidence interval
limits for mean and agreement limits.
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individuals are needed for a more definitive analysis of the
use of this imaging modality for the evaluation of muscle
mass in CKD patients.
The study was approved by the Ethics and Research
Committee of the Federal University of Juiz de Fora and
signed informed consent was obtained from all study parti-
cipants prior to data collection.
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